[
  {
    "ts": null,
    "headline": "Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union",
    "summary": "In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes with confirmed amyloid pathology Lecanemab is the first therapy that targets an underlying cause of the disease to be authorized in the EU for eligible people with early AD TOKYO and CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE)",
    "url": "https://finnhub.io/api/news?id=bdfd2130d40d7e82b4bedb4646486ba08ef1b6de87a6e3a19cab63b4dc244f9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744758000,
      "headline": "Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union",
      "id": 133932956,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes with confirmed amyloid pathology Lecanemab is the first therapy that targets an underlying cause of the disease to be authorized in the EU for eligible people with early AD TOKYO and CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE)",
      "url": "https://finnhub.io/api/news?id=bdfd2130d40d7e82b4bedb4646486ba08ef1b6de87a6e3a19cab63b4dc244f9c"
    }
  },
  {
    "ts": null,
    "headline": "Drug to Treat Underlying Causes of Alzheimer's Gets EU Marketing Approval",
    "summary": "By Connor Hart A drug that targets an underlying cause of Alzheimer's disease being commercialized by Eisai and Biogen has received marketing approval from the European Commission. The...",
    "url": "https://finnhub.io/api/news?id=0137e7da1ab3cf6d2dd3df655416d488d666c5e41e7dc70bee45323ab4427c8b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744747987,
      "headline": "Drug to Treat Underlying Causes of Alzheimer's Gets EU Marketing Approval",
      "id": 133929574,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "By Connor Hart A drug that targets an underlying cause of Alzheimer's disease being commercialized by Eisai and Biogen has received marketing approval from the European Commission. The...",
      "url": "https://finnhub.io/api/news?id=0137e7da1ab3cf6d2dd3df655416d488d666c5e41e7dc70bee45323ab4427c8b"
    }
  },
  {
    "ts": null,
    "headline": "EU authorizes Eisai-Biogen's drug for early Alzheimer's treatment",
    "summary": "The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than...",
    "url": "https://finnhub.io/api/news?id=189521f405d9025be1efe40ce70a709c746197ccfff3cbf7206877904998a8f5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744737202,
      "headline": "EU authorizes Eisai-Biogen's drug for early Alzheimer's treatment",
      "id": 133928949,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than...",
      "url": "https://finnhub.io/api/news?id=189521f405d9025be1efe40ce70a709c746197ccfff3cbf7206877904998a8f5"
    }
  },
  {
    "ts": null,
    "headline": "Biogen : European Commission Grants Marketing Authorization for Leqembi® (lecanemab)",
    "summary": "The European Commission has granted the amyloid-beta monoclonal antibody Leqembi® Marketing Authorization in the European Union . Lecanemab is indicated for the treatment of adult patients with a...",
    "url": "https://finnhub.io/api/news?id=7e68c3db43366af2f0c6b1490606de6889a3376750b52d2a483f1de5757574ae",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744727705,
      "headline": "Biogen : European Commission Grants Marketing Authorization for Leqembi® (lecanemab)",
      "id": 133927562,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "The European Commission has granted the amyloid-beta monoclonal antibody Leqembi® Marketing Authorization in the European Union . Lecanemab is indicated for the treatment of adult patients with a...",
      "url": "https://finnhub.io/api/news?id=7e68c3db43366af2f0c6b1490606de6889a3376750b52d2a483f1de5757574ae"
    }
  }
]